{"id":"ppi-amoxicillin-metronidazole-and-clarithromycin","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Taste disturbance (metallic taste from metronidazole)"},{"rate":"5-10","effect":"Headache"},{"rate":"1-3","effect":"Allergic reaction (amoxicillin)"}]},"_chembl":{"chemblId":"CHEMBL2105950","moleculeType":"Small molecule","molecularWeight":"387.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The proton pump inhibitor (PPI) reduces gastric acid to create an optimal environment for antibiotic activity. Amoxicillin, metronidazole, and clarithromycin are bactericidal/bacteriostatic agents that work synergistically to inhibit H. pylori protein synthesis and disrupt bacterial DNA, preventing resistance development through multi-drug targeting.","oneSentence":"This is a quadruple therapy regimen that eradicates Helicobacter pylori by combining acid suppression with three antibiotics that target bacterial protein synthesis and DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:06.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication in peptic ulcer disease"},{"name":"H. pylori-associated gastritis"}]},"trialDetails":[{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":"Helicobacter Pylori Infection","enrollment":337},{"nctId":"NCT07104318","phase":"PHASE3","title":"Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Helicobacter Pylori","enrollment":360},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT03431688","phase":"NA","title":"Tailored Therapy for Clarithromycin-Resistant H. Pylori","status":"COMPLETED","sponsor":"Kangdong Sacred Heart Hospital","startDate":"2018-10-01","conditions":"Helicobacter Pylori Infection","enrollment":782},{"nctId":"NCT06760065","phase":"PHASE3","title":"Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-15","conditions":"Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education","enrollment":316},{"nctId":"NCT05475431","phase":"","title":"Real-world Treatment of H. Pylori Eradication in Patients with Comorbidity","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-05-06","conditions":"Helicobacter Pylori Infection, Comorbidities and Coexisting Conditions, Real-world Outcome","enrollment":1053},{"nctId":"NCT04147065","phase":"PHASE4","title":"Helicobacter Pylori Eradication According to DPO-PCR Methods (K-CREATE) Study)","status":"RECRUITING","sponsor":"Incheon St.Mary's Hospital","startDate":"2021-07-14","conditions":"Helicobacter Pylori Infection","enrollment":1230},{"nctId":"NCT06382493","phase":"NA","title":"Tegoprazan-containing Sequential for H. Pylori","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2021-02-01","conditions":"Helicobacter Pylori Infection","enrollment":400},{"nctId":"NCT05664685","phase":"PHASE4","title":"Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-10-17","conditions":"Helicobacter Pylori Infection","enrollment":127},{"nctId":"NCT06315478","phase":"PHASE4","title":"Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-02-01","conditions":"H.Pylori Infection","enrollment":60},{"nctId":"NCT06275204","phase":"","title":"H. Pylori Screen-and-treat Study in a Population of Young Adults","status":"RECRUITING","sponsor":"University of Latvia","startDate":"2024-03-04","conditions":"Gastric Cancer, H Pylori Infection, H Pylori Eradication","enrollment":6800},{"nctId":"NCT01273441","phase":"PHASE4","title":"Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2010-12","conditions":"Helicobacter Pylori","enrollment":338},{"nctId":"NCT02373280","phase":"NA","title":"The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-08","conditions":"Helicobacter Infection","enrollment":600},{"nctId":"NCT02359331","phase":"NA","title":"The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection","status":"TERMINATED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-08","conditions":"Helicobacter Infection","enrollment":370},{"nctId":"NCT04660123","phase":"PHASE4","title":"A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-12-20","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Bismuth","enrollment":959},{"nctId":"NCT04853875","phase":"PHASE4","title":"ILTHPI - Comparison of Medicament Containing Tetracycline, Metronidazole, Bismuth Versus Amoxicillin, Metronidazole, Clarithromycin","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2021-04-19","conditions":"Helicobacter Pylori Infection","enrollment":104},{"nctId":"NCT05152004","phase":"NA","title":"Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2018-09-01","conditions":"Helicobacter Pylori Infection","enrollment":240},{"nctId":"NCT04178187","phase":"NA","title":"The Role of Probiotics in the Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Evangelismos Hospital","startDate":"2019-10-02","conditions":"Helicobacter Pylori Infection","enrollment":660},{"nctId":"NCT05191888","phase":"PHASE4","title":"14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2021-08-06","conditions":"Helicobacter Pylori Eradication","enrollment":906},{"nctId":"NCT04769583","phase":"PHASE4","title":"14-day Quadruple Therapy Versus Triple Therapy in HP Eradication","status":"COMPLETED","sponsor":"mohamed bouchoucha","startDate":"2019-02-10","conditions":"Gastritis H Pylori","enrollment":121},{"nctId":"NCT04721704","phase":"NA","title":"Comparison of Efficacy of Triple Regimen Based on Clarithromycin VS Metronidazole in Children","status":"UNKNOWN","sponsor":"Shaheed Zulfiqar Ali Bhutto Medical University","startDate":"2020-09-14","conditions":"H Pylori Gastritis","enrollment":36},{"nctId":"NCT04107194","phase":"PHASE3","title":"Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.","status":"UNKNOWN","sponsor":"University of Bari","startDate":"2020-01-14","conditions":"Helicobacter Pylori Infection, Antibiotic Resistant Infection, Antibiotic Resistant Strain","enrollment":362},{"nctId":"NCT04445948","phase":"PHASE4","title":"Lactoferrin in Helicobacter Pylori Eradication Either With Standard Triple Therapy or Sequential Therapy","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2019-11-30","conditions":"Helicobacter Pylori Infection","enrollment":400},{"nctId":"NCT03658746","phase":"PHASE4","title":"Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shandong University","startDate":"2019-01-01","conditions":"Helicobacter Pylori Infection","enrollment":420},{"nctId":"NCT02557932","phase":"PHASE3","title":"Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2015-09","conditions":"Helicobacter Pylori Infection, Family History of Stomach Cancer","enrollment":352},{"nctId":"NCT03837990","phase":"","title":"One Sequencing Find All for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2019-05-01","conditions":"Helicobacter Pylori Infection, Resistant Infection","enrollment":60},{"nctId":"NCT03219723","phase":"","title":"Drug Use Surveillance of Takecab for \"Supplement to Helicobacter Pylori Eradication\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-09-01","conditions":"Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other","enrollment":560},{"nctId":"NCT03884348","phase":"","title":"Tailored H. Pylori Eradication Based on Clarithromycin Resistance","status":"COMPLETED","sponsor":"Kangdong Sacred Heart Hospital","startDate":"2017-01-01","conditions":"Helicobacter Pylori Infection, Antibiotic Resistant Strain","enrollment":431},{"nctId":"NCT03383003","phase":"NA","title":"Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2016-03-01","conditions":"Helicobacter Pylori Infection","enrollment":240},{"nctId":"NCT02935010","phase":"PHASE4","title":"Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2017-02-05","conditions":"Helicobacter Pylori Infection","enrollment":382},{"nctId":"NCT03413020","phase":"PHASE4","title":"Tailored Therapy for Helicobacter Pylori Rescue Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-01-03","conditions":"Helicobacter Pylori Infection","enrollment":200},{"nctId":"NCT03583476","phase":"","title":"The Impact of Antibiotics MIC Value on the Efficacy of Treatment Regimens for Helicobacter Pylori Infection.","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2018-04-01","conditions":"Helicobacter Pylori Infection","enrollment":1821},{"nctId":"NCT03571230","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2018-07-01","conditions":"Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing","enrollment":400},{"nctId":"NCT02959255","phase":"PHASE4","title":"10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2017-01-30","conditions":"Helicobacter Pylori Infection","enrollment":364},{"nctId":"NCT02576236","phase":"NA","title":"Therapeutic Trial Comparing Triple Therapy Guided by the PCR Detection of Clarithromycin Resistance vs Empiric Concomitant Quadruple Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05","conditions":"H Pylori Infection Eradication, Antibiotics Therapeutic Strategies, H Pylori Eradication","enrollment":2500},{"nctId":"NCT03139253","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment","status":"UNKNOWN","sponsor":"Yanqing Li","startDate":"2017-05-30","conditions":"Antimicrobial Susceptibility Testing, Triple Therapy","enrollment":120},{"nctId":"NCT02988089","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2017-04-20","conditions":"Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing","enrollment":480},{"nctId":"NCT02359435","phase":"NA","title":"Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2012-10","conditions":"Helicobacter Pylori Infection","enrollment":440},{"nctId":"NCT01264822","phase":"","title":"Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-01-13","conditions":"Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive","enrollment":108},{"nctId":"NCT02934048","phase":"PHASE4","title":"Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2016-10","conditions":"Therapeutic Duration, Helicobacter Pylori, Antimicrobial Susceptibility Test","enrollment":700},{"nctId":"NCT02349685","phase":"NA","title":"The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-01","conditions":"Helicobacter Infection","enrollment":219},{"nctId":"NCT02741414","phase":"NA","title":"A Multi-center Study for Eradication of Refractory Helicobacter Pylori","status":"UNKNOWN","sponsor":"Taizhou Hospital","startDate":"2016-06","conditions":"Gastritis","enrollment":4428},{"nctId":"NCT02689583","phase":"NA","title":"A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2016-03","conditions":"Gastritis, Gastric Ulcer","enrollment":3000},{"nctId":"NCT02682446","phase":"","title":"The Efficacy of Serum Pepsinogen for Prediction of Metachronous Gastric Neoplasm","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2007-01","conditions":"Gastric Cancer","enrollment":800},{"nctId":"NCT02635191","phase":"PHASE4","title":"Tailored Therapy for Helicobacter Pylori in Children","status":"UNKNOWN","sponsor":"Beijing Children's Hospital","startDate":"2014-03","conditions":"Helicobacter Pylori Infection","enrollment":200},{"nctId":"NCT01085786","phase":"PHASE4","title":"Sequential and Hybrid Therapies for H Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2008-08","conditions":"Helicobacter Pylori Infection","enrollment":240},{"nctId":"NCT01481844","phase":"PHASE3","title":"Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection","status":"COMPLETED","sponsor":"Soroka University Medical Center","startDate":"2011-11","conditions":"Optimization of Second Line Treatment Protocol for H Pylori Eradication","enrollment":101},{"nctId":"NCT01888237","phase":"PHASE4","title":"High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2013-05","conditions":"Dyspepsia, Helicobacter-associated Gastritis, Stomach Disorders","enrollment":118},{"nctId":"NCT02175901","phase":"PHASE4","title":"Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2014-07","conditions":"Dyspepsia, Peptic Ulcer","enrollment":215},{"nctId":"NCT02092506","phase":"PHASE4","title":"RCT: Triple vs Sequential vs Concomitant Therapy H Pylori","status":"COMPLETED","sponsor":"Changi General Hospital","startDate":"2011-12","conditions":"Bacterial Infection Due to Helicobacter Pylori (H. Pylori)","enrollment":462},{"nctId":"NCT01168063","phase":"NA","title":"Molecular Detection of Antibiotic Resistance and H Pylori Eradication","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-02","conditions":"Helicobacter Pylori Infection","enrollment":1386},{"nctId":"NCT01887249","phase":"PHASE4","title":"15-day Sequential Therapy for Helicobacter Pylori Infection in Korea","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-05","conditions":"Helicobacter Pylori Infection","enrollment":287},{"nctId":"NCT01464060","phase":"PHASE4","title":"14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Infante, Javier Molina, M.D.","startDate":"2011-09","conditions":"Helicobacter Pylori Infection","enrollment":400},{"nctId":"NCT00719420","phase":"PHASE3","title":"Clarithromycin, Amoxicillin, and Metronidazole Based Regimens to Treat Helicobacter Pylori Infections in Colombia","status":"COMPLETED","sponsor":"University of North Texas Health Science Center","startDate":"2006-04","conditions":"Helicobacter Pylori Infection","enrollment":151},{"nctId":"NCT00154440","phase":"PHASE3","title":"Helicobacter - Lymphoma - Radiation Part I: Eradication, Part II: Radiation","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2001-11","conditions":"Lymphoma, Lymphoma, Non-Hodgkin","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"PPI, amoxicillin, metronidazole and clarithromycin","genericName":"PPI, amoxicillin, metronidazole and clarithromycin","companyName":"Infante, Javier Molina, M.D.","companyId":"infante-javier-molina-m-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a quadruple therapy regimen that eradicates Helicobacter pylori by combining acid suppression with three antibiotics that target bacterial protein synthesis and DNA. Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated gastritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}